Humana (HUM) Stock Price, News & Analysis

Company Overview

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans.

The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.

Humana was founded in 1961 as a nursing home company and later expanded into health insurance. Headquartered in Louisville, Kentucky, it has developed a business focused primarily on serving older adults and people enrolled in government-sponsored health programs.

Key Stats

• Today's Range: $434.09 to $450.00
• 50-Day Range: $371.93 to $446.33
• 52-Week Range: $163.11 to $456.50
• Volume: 1.94 million shs
• Average Volume: 1.52 million shs
• Market Capitalization: $53.17 billion
• P/E Ratio: 33.66
• Dividend Yield: 0.80%
• Price Target: $476.52
• Consensus Rating: Moderate Buy

Humana Stock Analysis - MarketRank™

Humana scored higher than 85% of companies evaluated by MarketBeat, and ranked 157th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Humana has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 1 strong buy rating, 21 buy ratings, 9 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Humana is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Humana has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 75.13%

Earnings Growth

Earnings for Humana are expected to grow by 75.13% in the coming year, from $9.69 to $16.97 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Humana is 33.66, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.24.

Price to Earnings Ratio vs. Sector

The P/E ratio of Humana is 33.66, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.34.

Price to Earnings Growth Ratio

Humana has a PEG Ratio of 2.12. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Humana has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.32% of the float of Humana has been sold short.

Short Interest Ratio / Days to Cover

Humana has a short interest ratio ("days to cover") of 2.15, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Humana has recently decreased by 24.16%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Humana has a dividend yield of 0.79%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Humana does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Humana is 34.44%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Humana will have a dividend payout ratio of 20.86% next year. This indicates that Humana will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.56

News Sentiment

Humana has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 55 news articles for Humana this week, compared to 10 articles on an average week.

Search Interest

Only 13 people have searched for HUM on MarketBeat in the last 30 days. This is a decrease of -52% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Humana to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Humana insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,384,006.00 in company stock.

Percentage Held by Insiders

0.20% of the stock of Humana is held by insiders.

Percentage Held by Institutions

92.38% of the stock of Humana is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 11/27 Dividend: 10/30/2026
• Ex-Dividend for 11/27 Dividend: 10/30/2026
• Last Earnings: 11/06/2026
• Today: 11/13/2026
• Dividend Payable: 11/27/2026
• Investor update: 12/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Managed Healthcare
• Current Symbol: NYSE:HUM
• CIK: 49071
• Web: www.humana.com
• Phone: (502) 580-1000
• Fax: 502-580-3639
• Employees: 67,060
• Year Founded: 1961

Price Target and Rating

• Average Price Target for Humana: $476.52
• High Price Target: $602.00
• Low Price Target: $195.00
• Potential Upside/Downside: +7.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.69
• Research Coverage: 32 Analysts

Profitability

• EPS (Trailing Twelve Months): $10.28
• Trailing P/E Ratio: 33.66
• Forward P/E Ratio: 26.09
• P/E Growth: 2.12
• Net Income: $1.19 billion
• Net Margins: 0.81%
• Pretax Margin: 1.14%
• Return on Equity: 8.50%
• Return on Assets: 2.90%

Debt

• Debt-to-Equity Ratio: 0.61
• Current Ratio: 1.65
• Quick Ratio: 1.74

Sales & Book Value

• Annual Sales: $129.66 billion
• Price / Sales: 0.41
• Cash Flow: $23.86 per share
• Price / Cash Flow: 18.55
• Book Value: $157.26 per share
• Price / Book: 2.81

Miscellaneous

• Outstanding Shares: 120,100,000
• Free Float: 119,863,000
• Market Cap: $53.17 billion
• Optionable: Optionable
• Beta: 0.65